VSBC · Vitaspring Biomedical Co. Ltd.
Market Cap
$2.30M
Shares
207.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2026
Net Income
-$415.37K
+46.4%
FY2026
Gross Margin
36.84%
-8.4pp
FY2022
Operating Margin
20.07%
-151.3pp
FY2022
Diluted EPS
$0.00
FY2026
Operating Cash Flow
-$2688
+81.7%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $5.61M | $248.2K | $15.14K | $17.18K | $16.23K | $0 | |
| — | — | — | — | — | — | — | $15.14K | — | — | — | |
| — | $0 | $0 | $0 | $3.33M | $3.55M | $136K | $13.45K | $3462 | $4889 | $0 | |
| — | $0 | $0 | $0 | -$3.33M | $2.07M | $112.2K | $1695 | $13.72K | $11.34K | $0 | |
| — | — | — | — | — | 36.84% | 45.21% | 11.2% | 79.85% | 69.88% | — | |
| — | — | — | — | $844.84K | $941.34K | $537.58K | $21.18K | $36.11K | $17.71K | $45 | |
| $392.11K | $385.41K | $679.91K | $1.12M | $844.84K | $941.34K | $537.58K | $21.18K | $36.11K | — | — | |
| — | — | $9957 | $15.06K | — | — | — | $450 | $450 | — | — | |
| -$43.87K | — | — | — | — | — | — | — | -$36.11K | -$17.71K | -$45 | |
| -$392.11K | -$385.41K | -$679.91K | -$1.12M | -$4.18M | $1.13M | $425.38K | $6919 | -$22.4K | -$6374 | — | |
| — | — | — | — | — | 20.07% | 171.39% | 45.7% | -130.36% | -39.27% | — | |
| — | — | -$669.96K | -$1.1M | — | — | — | $7369 | -$21.95K | — | — | |
| — | — | — | $0 | -$4.16M | $0 | $0 | $9030 | $0 | — | — | |
| — | — | — | — | — | — | -$425.38K | $6919 | -$22.4K | — | — | |
| -$392.11K | -$385.41K | -$679.91K | -$1.12M | -$4.17M | $1.13M | -$425.38K | $6919 | -$22.4K | — | — | |
| $18.56K | $29.96K | $95.01K | $0 | -$5381 | $217.1K | $0 | $0 | $0 | — | — | |
| -$410.67K | -$415.37K | -$774.92K | -$1.12M | -$4.16M | $909.56K | $425.38K | $6919 | -$22.4K | -$6374 | -$45 | |
| — | — | — | — | — | 16.2% | 171.39% | 45.7% | -130.36% | -39.27% | — | |
| — | — | — | — | — | — | — | — | -$22.4K | -$6374 | — | |
| USD/shares | $0.00 | $0.00 | $0.00 | -$0.01 | -$0.02 | $0.00 | — | — | — | — | — |
| shares | — | — | — | — | — | 205.98M | 91.09M | — | — | — | — |
| shares | — | 207.03M | 207.03M | 207.03M | 206.52M | 205.98M | 91.09M | 10.9M | 49.1M | 11.47M | 246.58K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.02×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 115 similar-size Biotechnology companies (of 514 listed).